KalVista Pharmaceuticals (KALV) Depreciation & Amortization (CF) (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported Depreciation & Amortization (CF) of $252000.0 for Q3 2025, up 12.5% on a YoY basis from $224000.0 in Q3 2024, and up 14.55% sequentially from $220000.0 in Q2 2025.
KalVista Pharmaceuticals (KALV) Depreciation & Amortization (CF) (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $252000.0 in Q3 2025.
- For the quarter ending Q3 2025, Depreciation & Amortization (CF) rose 12.5% year-over-year to $252000.0; the trailing twelve-month figure through Jul 2025 stood at $699000.0 (down 17.47% YoY), and the FY2025 full-year result was $900000.0, up 10.29% from the prior year.
- Depreciation & Amortization (CF) improved to $252000.0 in Q3 2025, from $220000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $252000.0 in Q3 2025 to a low of $127000.0 in Q4 2021.
- A 5-year average of $182166.7 and a median of $183000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) dropped 4.51% in 2021 and jumped 36.22% in 2022, its largest moves.
- Tracing KALV's Depreciation & Amortization (CF) over 5 years: stood at $127000.0 in 2021, then jumped by 36.22% to $173000.0 in 2022, then rose by 13.87% to $197000.0 in 2023, then gained by 15.23% to $227000.0 in 2024, then advanced by 11.01% to $252000.0 in 2025.
- Business Quant data shows KALV's Depreciation & Amortization (CF) at $252000.0 in Q3 2025, $220000.0 in Q2 2025, and $227000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | 252,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 252,000.00 |
| Jul 31, 2025 | 252,000.00 |
| Apr 30, 2025 | 220,000.00 |
| Apr 30, 2025 | 220,000.00 |
| Oct 31, 2024 | 227,000.00 |
| Oct 31, 2024 | 227,000.00 |
| Jul 31, 2024 | 224,000.00 |
| Jul 31, 2024 | 224,000.00 |
| Apr 30, 2024 | 219,000.00 |
| Apr 30, 2024 | 219,000.00 |
| Jan 31, 2024 | 207,000.00 |
| Jan 31, 2024 | 207,000.00 |
| Oct 31, 2023 | 197,000.00 |
| Oct 31, 2023 | 197,000.00 |
| Jul 31, 2023 | 193,000.00 |
| Jul 31, 2023 | 193,000.00 |
| Apr 30, 2023 | 170,000.00 |
| Apr 30, 2023 | 170,000.00 |
| Jan 31, 2023 | 199,000.00 |
| Jan 31, 2023 | 199,000.00 |